NurExone Biologic
NurExone Biologic is a US startup, founded in 2025. It has raised at least $5.8m in outside funding, according to its filings with the US Securities and Exchange Commission (Form D), which puts it at the early stage.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Funding
NurExone Biologic has raised at least $5.8m in outside funding, according to its Form D filings with the US Securities and Exchange Commission. Form D figures are a minimum: not every round is filed.
Related
Questions and answers
What does NurExone Biologic do?
NurExone Biologic is classed in biotechnology in its filings with the US Securities and Exchange Commission.
How much has NurExone Biologic raised?
At least $5.8m, according to its Form D filings with the US Securities and Exchange Commission.
Where is NurExone Biologic based?
NurExone Biologic is registered in Israel; its operating headquarters is not yet confirmed.
When was NurExone Biologic founded?
NurExone Biologic was founded in 2025.
Source record: SEC EDGAR (Form D filings).
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.